生物相似药市场按药物类别、治疗类型、分销管道和地区划分

2025 年全球生物相似药市场规模估计为 425.3 亿美元，预计到 2032 年将达到 1,363.7 亿美元，2025 年至 2032 年的复合年增长率为 18.1%。

图。

全球生物相似药市场的成长受到全球医疗成本的上涨和重磅生技药品专利到期的推动。生物相似药为癌症、糖尿病和自体免疫疾病等慢性病提供了经济实惠的治疗选择。与参考生技药品相比，生物相似药可以显着节省成本。例如，Filgrastim的生物相似药 Zardio 的上市价格比原始生技药品Neupogen 低 15%。美国、欧盟和日本等主要市场对生物相似药的监管核准也在增加，并遵循明确的指导方针，简化了生物相似药的市场准入。这导致许多新兴企业进入巨大且利润丰厚的生物相似药市场。

市场动态

全球生物相似药市场的成长受到全球慢性病盛行率上升和医疗保健预算有限的推动。这推动了对生技药品低成本生物相似药替代品的需求。预计在 2018-2026 年预测期内，许多重磅生技药品将失去专利保护，为生物相似药打开大门。例如，到 2024 年，Infliximab和Adalimumab是面临生物相似药竞争的收益最高的生技药品之一。大公司的监管核准、产品发布和扩大行销活动可能会推动市场成长。

研究的主要特点

• 本报告对全球生物相似药市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
• 它还强调了各个领域的潜在商机并说明了该市场的有吸引力的投资提案矩阵。
• 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，概述了全球生物相似药市场的主要企业。
• 本报告的见解将使负责人和公司经营团队能够就未来的产品发布、规模扩大、市场扩张和行销策略做出明智的决策。
• 全球生物相似药市场报告迎合了该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过全球生物相似药市场分析中使用的各种策略矩阵来促进他们的决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• 一致的机会图 (COM)

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 影响分析
• 市场趋势
• 监管情景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

第 4 章。

• 整体影响
• 政府倡议
• COVID-19 市场影响

5. 2020 年至 2032 年全球生物相似药市场（按药物类别划分）（十亿美元）

• 介绍
• 重组人体生长荷尔蒙
• 颗粒细胞增生因子
• 胰岛素
• 抗凝血剂
• 融合蛋白红血球生成素
• 单株抗体
• 促滤泡素
• 其他的

6. 2020 年至 2032 年全球生物相似药市场（按治疗类型划分）（十亿美元）

• 介绍
• 肿瘤学
• 免疫学
• 血液学
• 荷尔蒙疗法
• 代谢紊乱
• 其他的

7. 2020-2032 年全球生物相似药市场按通路划分（十亿美元）

• 介绍
• 医院药房
• 零售药局
• 专业药房

8. 2020 年至 2032 年全球生物相似药市场（按地区划分）（十亿美元）

• 介绍
• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第九章 竞争格局

• 公司简介
  • Amgen Inc.
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Celltrion Healthcare Co., Ltd.
  • Biocon Limited
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Fresenius Kabi AG
  • Merck &Co., Inc.
  • Biogen Idec Inc
  • Coherus BioSciences
  • Stada Arzneimittel AG

第 10 章分析师建议

• 兴衰
• 一致的机会地图

第 11 章 参考文献与调查方法

• 参考
• 调查方法

Global Biosimilars Market is estimated to be valued at USD 42.53 Bn in 2025 and is expected to reach USD 136.37 Bn by 2032, growing at a compound annual growth rate (CAGR) of 18.1% from 2025 to 2032.

Figure. Biosimilars Market Share (%), By Region 2025

Global biosimilars market growth is driven by rising healthcare costs worldwide and the expiration of blockbuster biologics patents. Biosimilars provide affordable treatment options for chronic diseases such as cancer, diabetes, and autoimmune disorders. These offer significant cost savings as compared to reference biologics. For example, Filgrastim's biosimilar Zarzio was launched at a 15% lower price compared to original biologic Neupogen. Regulatory approvals for biosimilars have also increased in major markets like the U.S, EU, and Japan following clear guidelines, thus, easing market entry. This has attracted many emerging players to the large and lucrative biosimilars market.

Market Dynamics:

Global biosimilars market growth is driven by factors like rising chronic disease prevalence rates worldwide coupled with limited healthcare budgets. This has boosted demand for lower-cost biosimilar alternatives to biologics. Many blockbusters biologic drugs are expected to lose patent protection over the forecast period 2018-2026, thus, offering potential for biosimilar entrants. For instance, infliximab and adalimumab are among the highest revenue earning biologics that faced biosimilar competition by 2024. Regulatory approvals and product launches, along with marketing expansion activities by major players can drive the market growth.

Key Features of the Study:

• This report provides in-depth analysis of the global biosimilars market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global biosimilars market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Novartis, Pfizer, Teva Pharmaceuticals, Celltrion, Biocon, Amgen, Samsung Biologics, Stada Arzneimittel AG.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biosimilars market.

Detailed Segmentation-

• By Drug Class
  • Recombinant Human Growth Hormone
  • Granulocyte Colony-Stimulating Factor
  • Insulin
  • Anticoagulants
  • Fusion Proteins Erythropoietin
  • Monoclonal Antibodies
  • Follitropin
  • Others
• By Therapy Type
  • Oncology
  • Immunology
  • Hematology
  • Hormone Therapy
  • Metabolic Disorders
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Amgen Inc.
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Celltrion Healthcare Co., Ltd.
  • Biocon Limited
  • Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Fresenius Kabi AG
  • Merck & Co., Inc.
  • Biogen Idec Inc
  • Coherus BioSciences
  • Stada Arzneimittel AG

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Therapy Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Biosimilars Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Biosimilars Market, By Drug Class, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Recombinant Human Growth Hormone
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Granulocyte Colony-Stimulating Factor
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Insulin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Anticoagulants
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Fusion Proteins Erythropoietin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Monoclonal Antibodies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Follitropin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Biosimilars Market, By Therapy Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oncology
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Immunology
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Hematology
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Hormone Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Metabolic Disorders
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Biosimilars Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Biosimilars Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • U.S.
  • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

• Company Profiles
  • Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Celltrion Healthcare Co., Ltd.
  • Biocon Limited
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Fresenius Kabi AG
  • Merck & Co., Inc.
  • Biogen Idec Inc
  • Coherus BioSciences
  • Stada Arzneimittel AG

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact

"